In July 2026, Prenetics Global Ltd closed a $1 billion growth financing deal with General Catalyst’s Customer Value Fund to fuel expansion of its IM8 health and longevity brand [S2]. This capital influx underpins the company’s pivot from its pandemic testing heritage toward prioritized subscription revenue growth via shifting new subscribers from monthly to higher-value quarterly plans, boosting average order value dramatically [S1][S3]. Prenetics aims to leverage its complementary genetic testing platform CircleDNA for cross-selling opportunities, supporting enhanced customer lifetime value [S1]. Despite strong liquidity with a current ratio over 2.0 [F1], sustainability of recurring revenue depends heavily on retention amid competitive pricing pressure and regulatory complexity across more than 30 countries served [S1].